nodes	percent_of_prediction	percent_of_DWPC	metapath
Boceprevir—ABCB1—Mitomycin—urinary bladder cancer	0.113	0.338	CbGbCtD
Boceprevir—CYP3A4—Thiotepa—urinary bladder cancer	0.0513	0.154	CbGbCtD
Boceprevir—CYP3A5—Etoposide—urinary bladder cancer	0.0356	0.107	CbGbCtD
Boceprevir—ABCB1—Gemcitabine—urinary bladder cancer	0.0325	0.0974	CbGbCtD
Boceprevir—ABCB1—Cisplatin—urinary bladder cancer	0.0236	0.0708	CbGbCtD
Boceprevir—ABCB1—Etoposide—urinary bladder cancer	0.0232	0.0695	CbGbCtD
Boceprevir—ABCB1—Doxorubicin—urinary bladder cancer	0.0158	0.0474	CbGbCtD
Boceprevir—ABCB1—Methotrexate—urinary bladder cancer	0.0153	0.0459	CbGbCtD
Boceprevir—CYP3A4—Etoposide—urinary bladder cancer	0.0139	0.0417	CbGbCtD
Boceprevir—CYP3A4—Doxorubicin—urinary bladder cancer	0.00948	0.0284	CbGbCtD
Boceprevir—CTSV—prostate gland—urinary bladder cancer	0.00942	0.0542	CbGeAlD
Boceprevir—CMA1—prostate gland—urinary bladder cancer	0.00899	0.0518	CbGeAlD
Boceprevir—CTSV—seminal vesicle—urinary bladder cancer	0.00796	0.0459	CbGeAlD
Boceprevir—CTSL—prostate gland—urinary bladder cancer	0.00769	0.0443	CbGeAlD
Boceprevir—CTSL—seminal vesicle—urinary bladder cancer	0.00651	0.0375	CbGeAlD
Boceprevir—CTSV—renal system—urinary bladder cancer	0.00642	0.037	CbGeAlD
Boceprevir—CMA1—smooth muscle tissue—urinary bladder cancer	0.00637	0.0367	CbGeAlD
Boceprevir—CTSK—prostate gland—urinary bladder cancer	0.00579	0.0334	CbGeAlD
Boceprevir—CTSL—epithelium—urinary bladder cancer	0.00565	0.0326	CbGeAlD
Boceprevir—CTSL—smooth muscle tissue—urinary bladder cancer	0.00545	0.0314	CbGeAlD
Boceprevir—CTSL—renal system—urinary bladder cancer	0.00524	0.0302	CbGeAlD
Boceprevir—CTSL—urethra—urinary bladder cancer	0.00515	0.0297	CbGeAlD
Boceprevir—CTSV—female reproductive system—urinary bladder cancer	0.00514	0.0296	CbGeAlD
Boceprevir—CTSS—prostate gland—urinary bladder cancer	0.00508	0.0293	CbGeAlD
Boceprevir—CMA1—female reproductive system—urinary bladder cancer	0.00491	0.0283	CbGeAlD
Boceprevir—CTSK—seminal vesicle—urinary bladder cancer	0.0049	0.0282	CbGeAlD
Boceprevir—CTSV—vagina—urinary bladder cancer	0.00465	0.0268	CbGeAlD
Boceprevir—CTSS—seminal vesicle—urinary bladder cancer	0.00429	0.0247	CbGeAlD
Boceprevir—CTSL—female reproductive system—urinary bladder cancer	0.0042	0.0242	CbGeAlD
Boceprevir—CTSK—smooth muscle tissue—urinary bladder cancer	0.0041	0.0236	CbGeAlD
Boceprevir—CTSK—renal system—urinary bladder cancer	0.00395	0.0228	CbGeAlD
Boceprevir—CTSK—urethra—urinary bladder cancer	0.00388	0.0224	CbGeAlD
Boceprevir—CTSL—vagina—urinary bladder cancer	0.0038	0.0219	CbGeAlD
Boceprevir—CTSS—smooth muscle tissue—urinary bladder cancer	0.0036	0.0207	CbGeAlD
Boceprevir—CYP3A4—urine—urinary bladder cancer	0.00353	0.0203	CbGeAlD
Boceprevir—CTSS—renal system—urinary bladder cancer	0.00346	0.0199	CbGeAlD
Boceprevir—CTSS—urethra—urinary bladder cancer	0.0034	0.0196	CbGeAlD
Boceprevir—CTSK—female reproductive system—urinary bladder cancer	0.00316	0.0182	CbGeAlD
Boceprevir—CMA1—lymph node—urinary bladder cancer	0.00287	0.0165	CbGeAlD
Boceprevir—CTSK—vagina—urinary bladder cancer	0.00286	0.0165	CbGeAlD
Boceprevir—CTSS—female reproductive system—urinary bladder cancer	0.00277	0.016	CbGeAlD
Boceprevir—CTSS—vagina—urinary bladder cancer	0.00251	0.0144	CbGeAlD
Boceprevir—CTSL—lymph node—urinary bladder cancer	0.00246	0.0141	CbGeAlD
Boceprevir—CTSK—lymph node—urinary bladder cancer	0.00185	0.0107	CbGeAlD
Boceprevir—CYP3A5—prostate gland—urinary bladder cancer	0.00169	0.00971	CbGeAlD
Boceprevir—CTSS—lymph node—urinary bladder cancer	0.00162	0.00934	CbGeAlD
Boceprevir—CYP3A5—renal system—urinary bladder cancer	0.00115	0.00662	CbGeAlD
Boceprevir—ABCB1—prostate gland—urinary bladder cancer	0.000896	0.00516	CbGeAlD
Boceprevir—CYP3A4—renal system—urinary bladder cancer	0.000863	0.00497	CbGeAlD
Boceprevir—CYP3A5—vagina—urinary bladder cancer	0.000832	0.0048	CbGeAlD
Boceprevir—ABCB1—seminal vesicle—urinary bladder cancer	0.000758	0.00436	CbGeAlD
Boceprevir—CYP3A4—female reproductive system—urinary bladder cancer	0.000691	0.00398	CbGeAlD
Boceprevir—ABCB1—epithelium—urinary bladder cancer	0.000658	0.00379	CbGeAlD
Boceprevir—ABCB1—renal system—urinary bladder cancer	0.000611	0.00352	CbGeAlD
Boceprevir—ABCB1—urethra—urinary bladder cancer	0.0006	0.00346	CbGeAlD
Boceprevir—ABCB1—female reproductive system—urinary bladder cancer	0.000489	0.00282	CbGeAlD
Boceprevir—ABCB1—vagina—urinary bladder cancer	0.000442	0.00255	CbGeAlD
Boceprevir—ABCB1—lymph node—urinary bladder cancer	0.000286	0.00165	CbGeAlD
Boceprevir—Rhinitis—Epirubicin—urinary bladder cancer	0.000152	0.000529	CcSEcCtD
Boceprevir—Body temperature increased—Etoposide—urinary bladder cancer	0.000151	0.000529	CcSEcCtD
Boceprevir—Abdominal pain—Etoposide—urinary bladder cancer	0.000151	0.000529	CcSEcCtD
Boceprevir—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000151	0.000529	CcSEcCtD
Boceprevir—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000151	0.000529	CcSEcCtD
Boceprevir—Eye disorder—Methotrexate—urinary bladder cancer	0.000151	0.000527	CcSEcCtD
Boceprevir—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000151	0.000527	CcSEcCtD
Boceprevir—Tinnitus—Methotrexate—urinary bladder cancer	0.000151	0.000526	CcSEcCtD
Boceprevir—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.00015	0.000525	CcSEcCtD
Boceprevir—Asthenia—Cisplatin—urinary bladder cancer	0.00015	0.000524	CcSEcCtD
Boceprevir—Pharyngitis—Epirubicin—urinary bladder cancer	0.00015	0.000524	CcSEcCtD
Boceprevir—Cardiac disorder—Methotrexate—urinary bladder cancer	0.00015	0.000524	CcSEcCtD
Boceprevir—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000149	0.000522	CcSEcCtD
Boceprevir—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000149	0.00052	CcSEcCtD
Boceprevir—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000149	0.000519	CcSEcCtD
Boceprevir—Urethral disorder—Epirubicin—urinary bladder cancer	0.000148	0.000518	CcSEcCtD
Boceprevir—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000147	0.000515	CcSEcCtD
Boceprevir—Epistaxis—Doxorubicin—urinary bladder cancer	0.000147	0.000513	CcSEcCtD
Boceprevir—Angiopathy—Methotrexate—urinary bladder cancer	0.000147	0.000512	CcSEcCtD
Boceprevir—Sinusitis—Doxorubicin—urinary bladder cancer	0.000146	0.000511	CcSEcCtD
Boceprevir—Immune system disorder—Methotrexate—urinary bladder cancer	0.000146	0.00051	CcSEcCtD
Boceprevir—Dizziness—Fluorouracil—urinary bladder cancer	0.000146	0.00051	CcSEcCtD
Boceprevir—Visual impairment—Epirubicin—urinary bladder cancer	0.000146	0.000509	CcSEcCtD
Boceprevir—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000146	0.000509	CcSEcCtD
Boceprevir—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000145	0.000508	CcSEcCtD
Boceprevir—Chills—Methotrexate—urinary bladder cancer	0.000145	0.000506	CcSEcCtD
Boceprevir—Diarrhoea—Cisplatin—urinary bladder cancer	0.000143	0.0005	CcSEcCtD
Boceprevir—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000143	0.000499	CcSEcCtD
Boceprevir—Alopecia—Methotrexate—urinary bladder cancer	0.000143	0.000499	CcSEcCtD
Boceprevir—Vomiting—Gemcitabine—urinary bladder cancer	0.000143	0.000498	CcSEcCtD
Boceprevir—Mental disorder—Methotrexate—urinary bladder cancer	0.000141	0.000494	CcSEcCtD
Boceprevir—Rash—Gemcitabine—urinary bladder cancer	0.000141	0.000494	CcSEcCtD
Boceprevir—Dermatitis—Gemcitabine—urinary bladder cancer	0.000141	0.000494	CcSEcCtD
Boceprevir—Eye disorder—Epirubicin—urinary bladder cancer	0.000141	0.000494	CcSEcCtD
Boceprevir—Hypersensitivity—Etoposide—urinary bladder cancer	0.000141	0.000493	CcSEcCtD
Boceprevir—Tinnitus—Epirubicin—urinary bladder cancer	0.000141	0.000492	CcSEcCtD
Boceprevir—Malnutrition—Methotrexate—urinary bladder cancer	0.000141	0.000491	CcSEcCtD
Boceprevir—Erythema—Methotrexate—urinary bladder cancer	0.000141	0.000491	CcSEcCtD
Boceprevir—Headache—Gemcitabine—urinary bladder cancer	0.000141	0.000491	CcSEcCtD
Boceprevir—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00014	0.00049	CcSEcCtD
Boceprevir—Flushing—Epirubicin—urinary bladder cancer	0.00014	0.00049	CcSEcCtD
Boceprevir—Vomiting—Fluorouracil—urinary bladder cancer	0.00014	0.00049	CcSEcCtD
Boceprevir—Rhinitis—Doxorubicin—urinary bladder cancer	0.00014	0.00049	CcSEcCtD
Boceprevir—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000139	0.000486	CcSEcCtD
Boceprevir—Rash—Fluorouracil—urinary bladder cancer	0.000139	0.000486	CcSEcCtD
Boceprevir—Dermatitis—Fluorouracil—urinary bladder cancer	0.000139	0.000485	CcSEcCtD
Boceprevir—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000139	0.000485	CcSEcCtD
Boceprevir—Headache—Fluorouracil—urinary bladder cancer	0.000138	0.000483	CcSEcCtD
Boceprevir—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000138	0.000483	CcSEcCtD
Boceprevir—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000138	0.000481	CcSEcCtD
Boceprevir—Dysgeusia—Methotrexate—urinary bladder cancer	0.000138	0.000481	CcSEcCtD
Boceprevir—Asthenia—Etoposide—urinary bladder cancer	0.000137	0.00048	CcSEcCtD
Boceprevir—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000137	0.00048	CcSEcCtD
Boceprevir—Angiopathy—Epirubicin—urinary bladder cancer	0.000137	0.000479	CcSEcCtD
Boceprevir—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000137	0.000479	CcSEcCtD
Boceprevir—Immune system disorder—Epirubicin—urinary bladder cancer	0.000136	0.000477	CcSEcCtD
Boceprevir—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000136	0.000476	CcSEcCtD
Boceprevir—Back pain—Methotrexate—urinary bladder cancer	0.000136	0.000475	CcSEcCtD
Boceprevir—Chills—Epirubicin—urinary bladder cancer	0.000136	0.000474	CcSEcCtD
Boceprevir—Pruritus—Etoposide—urinary bladder cancer	0.000136	0.000474	CcSEcCtD
Boceprevir—Arrhythmia—Epirubicin—urinary bladder cancer	0.000135	0.000472	CcSEcCtD
Boceprevir—Visual impairment—Doxorubicin—urinary bladder cancer	0.000135	0.000471	CcSEcCtD
Boceprevir—Alopecia—Epirubicin—urinary bladder cancer	0.000134	0.000467	CcSEcCtD
Boceprevir—Nausea—Gemcitabine—urinary bladder cancer	0.000133	0.000466	CcSEcCtD
Boceprevir—Vomiting—Cisplatin—urinary bladder cancer	0.000133	0.000465	CcSEcCtD
Boceprevir—Vision blurred—Methotrexate—urinary bladder cancer	0.000132	0.000463	CcSEcCtD
Boceprevir—Mental disorder—Epirubicin—urinary bladder cancer	0.000132	0.000463	CcSEcCtD
Boceprevir—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000132	0.000462	CcSEcCtD
Boceprevir—Rash—Cisplatin—urinary bladder cancer	0.000132	0.000461	CcSEcCtD
Boceprevir—Dermatitis—Cisplatin—urinary bladder cancer	0.000132	0.00046	CcSEcCtD
Boceprevir—Malnutrition—Epirubicin—urinary bladder cancer	0.000132	0.00046	CcSEcCtD
Boceprevir—Erythema—Epirubicin—urinary bladder cancer	0.000132	0.00046	CcSEcCtD
Boceprevir—Diarrhoea—Etoposide—urinary bladder cancer	0.000131	0.000458	CcSEcCtD
Boceprevir—Nausea—Fluorouracil—urinary bladder cancer	0.000131	0.000458	CcSEcCtD
Boceprevir—Eye disorder—Doxorubicin—urinary bladder cancer	0.000131	0.000457	CcSEcCtD
Boceprevir—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.00013	0.000456	CcSEcCtD
Boceprevir—Tinnitus—Doxorubicin—urinary bladder cancer	0.00013	0.000456	CcSEcCtD
Boceprevir—Anaemia—Methotrexate—urinary bladder cancer	0.00013	0.000454	CcSEcCtD
Boceprevir—Flushing—Doxorubicin—urinary bladder cancer	0.00013	0.000453	CcSEcCtD
Boceprevir—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.00013	0.000453	CcSEcCtD
Boceprevir—Flatulence—Epirubicin—urinary bladder cancer	0.00013	0.000453	CcSEcCtD
Boceprevir—CTSL—Adaptive Immune System—CDKN1A—urinary bladder cancer	0.000129	0.000624	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—CDKN1A—urinary bladder cancer	0.000129	0.000624	CbGpPWpGaD
Boceprevir—Dysgeusia—Epirubicin—urinary bladder cancer	0.000129	0.00045	CcSEcCtD
Boceprevir—CTSV—Adaptive Immune System—PTEN—urinary bladder cancer	0.000129	0.000623	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—PTEN—urinary bladder cancer	0.000129	0.000623	CbGpPWpGaD
Boceprevir—CTSV—Immune System—FGFR3—urinary bladder cancer	0.000128	0.000622	CbGpPWpGaD
Boceprevir—CTSL—Immune System—FGFR3—urinary bladder cancer	0.000128	0.000622	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—CREBBP—urinary bladder cancer	0.000128	0.00062	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—EP300—urinary bladder cancer	0.000128	0.000619	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—EP300—urinary bladder cancer	0.000128	0.000619	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IFNA2—urinary bladder cancer	0.000127	0.000617	CbGpPWpGaD
Boceprevir—Back pain—Epirubicin—urinary bladder cancer	0.000127	0.000445	CcSEcCtD
Boceprevir—Angiopathy—Doxorubicin—urinary bladder cancer	0.000127	0.000443	CcSEcCtD
Boceprevir—Malaise—Methotrexate—urinary bladder cancer	0.000127	0.000443	CcSEcCtD
Boceprevir—Dizziness—Etoposide—urinary bladder cancer	0.000127	0.000443	CcSEcCtD
Boceprevir—Muscle spasms—Epirubicin—urinary bladder cancer	0.000126	0.000442	CcSEcCtD
Boceprevir—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000126	0.000441	CcSEcCtD
Boceprevir—Vertigo—Methotrexate—urinary bladder cancer	0.000126	0.000441	CcSEcCtD
Boceprevir—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000126	0.00044	CcSEcCtD
Boceprevir—Leukopenia—Methotrexate—urinary bladder cancer	0.000126	0.00044	CcSEcCtD
Boceprevir—Chills—Doxorubicin—urinary bladder cancer	0.000125	0.000438	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—ERBB2—urinary bladder cancer	0.000125	0.000605	CbGpPWpGaD
Boceprevir—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000125	0.000437	CcSEcCtD
Boceprevir—CTSV—Innate Immune System—SRC—urinary bladder cancer	0.000124	0.000602	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—SRC—urinary bladder cancer	0.000124	0.000602	CbGpPWpGaD
Boceprevir—Nausea—Cisplatin—urinary bladder cancer	0.000124	0.000434	CcSEcCtD
Boceprevir—Vision blurred—Epirubicin—urinary bladder cancer	0.000124	0.000433	CcSEcCtD
Boceprevir—Alopecia—Doxorubicin—urinary bladder cancer	0.000124	0.000432	CcSEcCtD
Boceprevir—Cough—Methotrexate—urinary bladder cancer	0.000123	0.000429	CcSEcCtD
Boceprevir—Mental disorder—Doxorubicin—urinary bladder cancer	0.000123	0.000428	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—CDH1—urinary bladder cancer	0.000122	0.000591	CbGpPWpGaD
Boceprevir—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000122	0.000427	CcSEcCtD
Boceprevir—Vomiting—Etoposide—urinary bladder cancer	0.000122	0.000426	CcSEcCtD
Boceprevir—Malnutrition—Doxorubicin—urinary bladder cancer	0.000122	0.000425	CcSEcCtD
Boceprevir—Erythema—Doxorubicin—urinary bladder cancer	0.000122	0.000425	CcSEcCtD
Boceprevir—Anaemia—Epirubicin—urinary bladder cancer	0.000122	0.000425	CcSEcCtD
Boceprevir—CMA1—Metabolism of proteins—CXCL8—urinary bladder cancer	0.000121	0.000586	CbGpPWpGaD
Boceprevir—Agitation—Epirubicin—urinary bladder cancer	0.000121	0.000422	CcSEcCtD
Boceprevir—Rash—Etoposide—urinary bladder cancer	0.000121	0.000422	CcSEcCtD
Boceprevir—Dermatitis—Etoposide—urinary bladder cancer	0.000121	0.000422	CcSEcCtD
Boceprevir—CTSS—Immune System—S100B—urinary bladder cancer	0.000121	0.000583	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00012	0.000582	CbGpPWpGaD
Boceprevir—Headache—Etoposide—urinary bladder cancer	0.00012	0.000419	CcSEcCtD
Boceprevir—Flatulence—Doxorubicin—urinary bladder cancer	0.00012	0.000419	CcSEcCtD
Boceprevir—Myalgia—Methotrexate—urinary bladder cancer	0.00012	0.000418	CcSEcCtD
Boceprevir—Arthralgia—Methotrexate—urinary bladder cancer	0.00012	0.000418	CcSEcCtD
Boceprevir—Chest pain—Methotrexate—urinary bladder cancer	0.00012	0.000418	CcSEcCtD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.00012	0.000579	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000119	0.000578	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—SRC—urinary bladder cancer	0.000119	0.000578	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—SRC—urinary bladder cancer	0.000119	0.000578	CbGpPWpGaD
Boceprevir—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000119	0.000417	CcSEcCtD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000119	0.000415	CcSEcCtD
Boceprevir—Malaise—Epirubicin—urinary bladder cancer	0.000119	0.000415	CcSEcCtD
Boceprevir—Discomfort—Methotrexate—urinary bladder cancer	0.000118	0.000413	CcSEcCtD
Boceprevir—Vertigo—Epirubicin—urinary bladder cancer	0.000118	0.000413	CcSEcCtD
Boceprevir—Syncope—Epirubicin—urinary bladder cancer	0.000118	0.000412	CcSEcCtD
Boceprevir—Leukopenia—Epirubicin—urinary bladder cancer	0.000118	0.000411	CcSEcCtD
Boceprevir—Back pain—Doxorubicin—urinary bladder cancer	0.000118	0.000411	CcSEcCtD
Boceprevir—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000117	0.000409	CcSEcCtD
Boceprevir—CYP3A5—Biological oxidations—GSTP1—urinary bladder cancer	0.000116	0.000564	CbGpPWpGaD
Boceprevir—Palpitations—Epirubicin—urinary bladder cancer	0.000116	0.000406	CcSEcCtD
Boceprevir—Confusional state—Methotrexate—urinary bladder cancer	0.000116	0.000404	CcSEcCtD
Boceprevir—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000116	0.000404	CcSEcCtD
Boceprevir—CYP3A5—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000115	0.000556	CbGpPWpGaD
Boceprevir—Cough—Epirubicin—urinary bladder cancer	0.000115	0.000401	CcSEcCtD
Boceprevir—Vision blurred—Doxorubicin—urinary bladder cancer	0.000115	0.000401	CcSEcCtD
Boceprevir—Infection—Methotrexate—urinary bladder cancer	0.000114	0.000398	CcSEcCtD
Boceprevir—Nausea—Etoposide—urinary bladder cancer	0.000114	0.000398	CcSEcCtD
Boceprevir—Hypertension—Epirubicin—urinary bladder cancer	0.000114	0.000397	CcSEcCtD
Boceprevir—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000113	0.000395	CcSEcCtD
Boceprevir—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000113	0.000393	CcSEcCtD
Boceprevir—Anaemia—Doxorubicin—urinary bladder cancer	0.000113	0.000393	CcSEcCtD
Boceprevir—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000112	0.000393	CcSEcCtD
Boceprevir—Myalgia—Epirubicin—urinary bladder cancer	0.000112	0.000391	CcSEcCtD
Boceprevir—Arthralgia—Epirubicin—urinary bladder cancer	0.000112	0.000391	CcSEcCtD
Boceprevir—Chest pain—Epirubicin—urinary bladder cancer	0.000112	0.000391	CcSEcCtD
Boceprevir—Agitation—Doxorubicin—urinary bladder cancer	0.000112	0.000391	CcSEcCtD
Boceprevir—Anxiety—Epirubicin—urinary bladder cancer	0.000112	0.00039	CcSEcCtD
Boceprevir—Skin disorder—Methotrexate—urinary bladder cancer	0.000111	0.000389	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—CDKN1A—urinary bladder cancer	0.000111	0.000539	CbGpPWpGaD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000111	0.000389	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—PTEN—urinary bladder cancer	0.000111	0.000538	CbGpPWpGaD
Boceprevir—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000111	0.000388	CcSEcCtD
Boceprevir—Discomfort—Epirubicin—urinary bladder cancer	0.000111	0.000387	CcSEcCtD
Boceprevir—Malaise—Doxorubicin—urinary bladder cancer	0.00011	0.000384	CcSEcCtD
Boceprevir—Dry mouth—Epirubicin—urinary bladder cancer	0.00011	0.000383	CcSEcCtD
Boceprevir—Vertigo—Doxorubicin—urinary bladder cancer	0.000109	0.000382	CcSEcCtD
Boceprevir—CTSL—Immune System—CREBBP—urinary bladder cancer	0.000109	0.000529	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CREBBP—urinary bladder cancer	0.000109	0.000529	CbGpPWpGaD
Boceprevir—Syncope—Doxorubicin—urinary bladder cancer	0.000109	0.000381	CcSEcCtD
Boceprevir—CTSV—Innate Immune System—EGFR—urinary bladder cancer	0.000109	0.000527	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—EGFR—urinary bladder cancer	0.000109	0.000527	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000109	0.000527	CbGpPWpGaD
Boceprevir—Leukopenia—Doxorubicin—urinary bladder cancer	0.000109	0.000381	CcSEcCtD
Boceprevir—CTSL—Immune System—CDH1—urinary bladder cancer	0.000109	0.000525	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CDH1—urinary bladder cancer	0.000109	0.000525	CbGpPWpGaD
Boceprevir—Confusional state—Epirubicin—urinary bladder cancer	0.000108	0.000378	CcSEcCtD
Boceprevir—Palpitations—Doxorubicin—urinary bladder cancer	0.000108	0.000376	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—ERBB2—urinary bladder cancer	0.000107	0.000519	CbGpPWpGaD
Boceprevir—Hypotension—Methotrexate—urinary bladder cancer	0.000107	0.000375	CcSEcCtD
Boceprevir—CYP3A5—Biological oxidations—GSTM1—urinary bladder cancer	0.000107	0.000518	CbGpPWpGaD
Boceprevir—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000107	0.000374	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—CDKN1A—urinary bladder cancer	0.000107	0.000517	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—PTEN—urinary bladder cancer	0.000107	0.000516	CbGpPWpGaD
Boceprevir—Infection—Epirubicin—urinary bladder cancer	0.000107	0.000373	CcSEcCtD
Boceprevir—CTSK—Immune System—FGFR3—urinary bladder cancer	0.000106	0.000515	CbGpPWpGaD
Boceprevir—Cough—Doxorubicin—urinary bladder cancer	0.000106	0.000371	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—S100B—urinary bladder cancer	0.000106	0.000514	CbGpPWpGaD
Boceprevir—CTSK—Innate Immune System—EP300—urinary bladder cancer	0.000106	0.000513	CbGpPWpGaD
Boceprevir—Shock—Epirubicin—urinary bladder cancer	0.000106	0.000369	CcSEcCtD
Boceprevir—CYP3A5—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000106	0.000511	CbGpPWpGaD
Boceprevir—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000105	0.000368	CcSEcCtD
Boceprevir—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000105	0.000367	CcSEcCtD
Boceprevir—Hypertension—Doxorubicin—urinary bladder cancer	0.000105	0.000367	CcSEcCtD
Boceprevir—Tachycardia—Epirubicin—urinary bladder cancer	0.000105	0.000366	CcSEcCtD
Boceprevir—CTSL—Adaptive Immune System—EGFR—urinary bladder cancer	0.000105	0.000506	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—EGFR—urinary bladder cancer	0.000105	0.000506	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000105	0.000365	CcSEcCtD
Boceprevir—Skin disorder—Epirubicin—urinary bladder cancer	0.000104	0.000364	CcSEcCtD
Boceprevir—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000104	0.000363	CcSEcCtD
Boceprevir—Insomnia—Methotrexate—urinary bladder cancer	0.000104	0.000363	CcSEcCtD
Boceprevir—Arthralgia—Doxorubicin—urinary bladder cancer	0.000104	0.000362	CcSEcCtD
Boceprevir—Chest pain—Doxorubicin—urinary bladder cancer	0.000104	0.000362	CcSEcCtD
Boceprevir—Myalgia—Doxorubicin—urinary bladder cancer	0.000104	0.000362	CcSEcCtD
Boceprevir—Anxiety—Doxorubicin—urinary bladder cancer	0.000103	0.000361	CcSEcCtD
Boceprevir—Paraesthesia—Methotrexate—urinary bladder cancer	0.000103	0.00036	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—SRC—urinary bladder cancer	0.000103	0.000498	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—ERBB2—urinary bladder cancer	0.000103	0.000498	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—KRAS—urinary bladder cancer	0.000103	0.000498	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—KRAS—urinary bladder cancer	0.000103	0.000498	CbGpPWpGaD
Boceprevir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000103	0.00036	CcSEcCtD
Boceprevir—Discomfort—Doxorubicin—urinary bladder cancer	0.000102	0.000358	CcSEcCtD
Boceprevir—Dyspnoea—Methotrexate—urinary bladder cancer	0.000102	0.000357	CcSEcCtD
Boceprevir—Dry mouth—Doxorubicin—urinary bladder cancer	0.000101	0.000354	CcSEcCtD
Boceprevir—Dyspepsia—Methotrexate—urinary bladder cancer	0.000101	0.000353	CcSEcCtD
Boceprevir—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000101	0.000487	CbGpPWpGaD
Boceprevir—Hypotension—Epirubicin—urinary bladder cancer	0.0001	0.000351	CcSEcCtD
Boceprevir—Confusional state—Doxorubicin—urinary bladder cancer	0.0001	0.00035	CcSEcCtD
Boceprevir—Decreased appetite—Methotrexate—urinary bladder cancer	9.97e-05	0.000349	CcSEcCtD
Boceprevir—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	9.94e-05	0.000481	CbGpPWpGaD
Boceprevir—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.9e-05	0.000346	CcSEcCtD
Boceprevir—CTSK—Adaptive Immune System—SRC—urinary bladder cancer	9.89e-05	0.000479	CbGpPWpGaD
Boceprevir—Fatigue—Methotrexate—urinary bladder cancer	9.89e-05	0.000346	CcSEcCtD
Boceprevir—CTSL—Adaptive Immune System—KRAS—urinary bladder cancer	9.88e-05	0.000478	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—KRAS—urinary bladder cancer	9.88e-05	0.000478	CbGpPWpGaD
Boceprevir—Infection—Doxorubicin—urinary bladder cancer	9.87e-05	0.000345	CcSEcCtD
Boceprevir—Pain—Methotrexate—urinary bladder cancer	9.81e-05	0.000343	CcSEcCtD
Boceprevir—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	9.78e-05	0.000342	CcSEcCtD
Boceprevir—Shock—Doxorubicin—urinary bladder cancer	9.77e-05	0.000342	CcSEcCtD
Boceprevir—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.74e-05	0.00034	CcSEcCtD
Boceprevir—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.73e-05	0.00034	CcSEcCtD
Boceprevir—Insomnia—Epirubicin—urinary bladder cancer	9.71e-05	0.000339	CcSEcCtD
Boceprevir—Tachycardia—Doxorubicin—urinary bladder cancer	9.7e-05	0.000339	CcSEcCtD
Boceprevir—Skin disorder—Doxorubicin—urinary bladder cancer	9.65e-05	0.000337	CcSEcCtD
Boceprevir—Paraesthesia—Epirubicin—urinary bladder cancer	9.64e-05	0.000337	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	9.62e-05	0.000465	CbGpPWpGaD
Boceprevir—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.6e-05	0.000336	CcSEcCtD
Boceprevir—Dyspnoea—Epirubicin—urinary bladder cancer	9.57e-05	0.000334	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—NCOR1—urinary bladder cancer	9.55e-05	0.000462	CbGpPWpGaD
Boceprevir—Feeling abnormal—Methotrexate—urinary bladder cancer	9.45e-05	0.00033	CcSEcCtD
Boceprevir—Dyspepsia—Epirubicin—urinary bladder cancer	9.45e-05	0.00033	CcSEcCtD
Boceprevir—Gastrointestinal pain—Methotrexate—urinary bladder cancer	9.38e-05	0.000328	CcSEcCtD
Boceprevir—Decreased appetite—Epirubicin—urinary bladder cancer	9.33e-05	0.000326	CcSEcCtD
Boceprevir—Hypotension—Doxorubicin—urinary bladder cancer	9.28e-05	0.000324	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	9.27e-05	0.000324	CcSEcCtD
Boceprevir—Fatigue—Epirubicin—urinary bladder cancer	9.26e-05	0.000323	CcSEcCtD
Boceprevir—Pain—Epirubicin—urinary bladder cancer	9.18e-05	0.000321	CcSEcCtD
Boceprevir—Constipation—Epirubicin—urinary bladder cancer	9.18e-05	0.000321	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—CDKN1A—urinary bladder cancer	9.17e-05	0.000444	CbGpPWpGaD
Boceprevir—CTSL—Immune System—ERBB2—urinary bladder cancer	9.16e-05	0.000443	CbGpPWpGaD
Boceprevir—CTSV—Immune System—ERBB2—urinary bladder cancer	9.16e-05	0.000443	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—PTEN—urinary bladder cancer	9.15e-05	0.000443	CbGpPWpGaD
Boceprevir—Urticaria—Methotrexate—urinary bladder cancer	9.11e-05	0.000318	CcSEcCtD
Boceprevir—Body temperature increased—Methotrexate—urinary bladder cancer	9.07e-05	0.000317	CcSEcCtD
Boceprevir—Abdominal pain—Methotrexate—urinary bladder cancer	9.07e-05	0.000317	CcSEcCtD
Boceprevir—CTSK—Immune System—CREBBP—urinary bladder cancer	9.06e-05	0.000438	CbGpPWpGaD
Boceprevir—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	9.05e-05	0.000316	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—EGFR—urinary bladder cancer	9.03e-05	0.000437	CbGpPWpGaD
Boceprevir—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	9.01e-05	0.000436	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CDH1—urinary bladder cancer	8.99e-05	0.000435	CbGpPWpGaD
Boceprevir—Insomnia—Doxorubicin—urinary bladder cancer	8.99e-05	0.000314	CcSEcCtD
Boceprevir—Paraesthesia—Doxorubicin—urinary bladder cancer	8.92e-05	0.000312	CcSEcCtD
Boceprevir—Dyspnoea—Doxorubicin—urinary bladder cancer	8.86e-05	0.000309	CcSEcCtD
Boceprevir—Feeling abnormal—Epirubicin—urinary bladder cancer	8.85e-05	0.000309	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—CDKN1A—urinary bladder cancer	8.8e-05	0.000426	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—PTEN—urinary bladder cancer	8.78e-05	0.000425	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Epirubicin—urinary bladder cancer	8.78e-05	0.000307	CcSEcCtD
Boceprevir—CTSS—Immune System—FGFR3—urinary bladder cancer	8.76e-05	0.000424	CbGpPWpGaD
Boceprevir—CTSL—Innate Immune System—HRAS—urinary bladder cancer	8.75e-05	0.000423	CbGpPWpGaD
Boceprevir—CTSV—Innate Immune System—HRAS—urinary bladder cancer	8.75e-05	0.000423	CbGpPWpGaD
Boceprevir—Dyspepsia—Doxorubicin—urinary bladder cancer	8.74e-05	0.000306	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—EP300—urinary bladder cancer	8.72e-05	0.000422	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—EGFR—urinary bladder cancer	8.67e-05	0.00042	CbGpPWpGaD
Boceprevir—Decreased appetite—Doxorubicin—urinary bladder cancer	8.64e-05	0.000302	CcSEcCtD
Boceprevir—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.58e-05	0.0003	CcSEcCtD
Boceprevir—Fatigue—Doxorubicin—urinary bladder cancer	8.56e-05	0.000299	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—KRAS—urinary bladder cancer	8.53e-05	0.000413	CbGpPWpGaD
Boceprevir—Urticaria—Epirubicin—urinary bladder cancer	8.53e-05	0.000298	CcSEcCtD
Boceprevir—Constipation—Doxorubicin—urinary bladder cancer	8.5e-05	0.000297	CcSEcCtD
Boceprevir—Pain—Doxorubicin—urinary bladder cancer	8.5e-05	0.000297	CcSEcCtD
Boceprevir—Body temperature increased—Epirubicin—urinary bladder cancer	8.49e-05	0.000297	CcSEcCtD
Boceprevir—Abdominal pain—Epirubicin—urinary bladder cancer	8.49e-05	0.000297	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—SRC—urinary bladder cancer	8.48e-05	0.00041	CbGpPWpGaD
Boceprevir—Hypersensitivity—Methotrexate—urinary bladder cancer	8.45e-05	0.000295	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—TERT—urinary bladder cancer	8.41e-05	0.000407	CbGpPWpGaD
Boceprevir—CTSV—Adaptive Immune System—HRAS—urinary bladder cancer	8.4e-05	0.000407	CbGpPWpGaD
Boceprevir—CTSL—Adaptive Immune System—HRAS—urinary bladder cancer	8.4e-05	0.000407	CbGpPWpGaD
Boceprevir—CTSL—Immune System—IL2—urinary bladder cancer	8.3e-05	0.000402	CbGpPWpGaD
Boceprevir—CTSV—Immune System—IL2—urinary bladder cancer	8.3e-05	0.000402	CbGpPWpGaD
Boceprevir—Asthenia—Methotrexate—urinary bladder cancer	8.23e-05	0.000288	CcSEcCtD
Boceprevir—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	8.23e-05	0.000398	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—KRAS—urinary bladder cancer	8.19e-05	0.000396	CbGpPWpGaD
Boceprevir—Feeling abnormal—Doxorubicin—urinary bladder cancer	8.19e-05	0.000286	CcSEcCtD
Boceprevir—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	8.15e-05	0.000394	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—SRC—urinary bladder cancer	8.15e-05	0.000394	CbGpPWpGaD
Boceprevir—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	8.12e-05	0.000284	CcSEcCtD
Boceprevir—Pruritus—Methotrexate—urinary bladder cancer	8.12e-05	0.000284	CcSEcCtD
Boceprevir—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	8.05e-05	0.00039	CbGpPWpGaD
Boceprevir—Hypersensitivity—Epirubicin—urinary bladder cancer	7.91e-05	0.000276	CcSEcCtD
Boceprevir—Urticaria—Doxorubicin—urinary bladder cancer	7.89e-05	0.000276	CcSEcCtD
Boceprevir—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	7.88e-05	0.000381	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	7.86e-05	0.000381	CbGpPWpGaD
Boceprevir—Abdominal pain—Doxorubicin—urinary bladder cancer	7.85e-05	0.000274	CcSEcCtD
Boceprevir—Body temperature increased—Doxorubicin—urinary bladder cancer	7.85e-05	0.000274	CcSEcCtD
Boceprevir—Diarrhoea—Methotrexate—urinary bladder cancer	7.85e-05	0.000274	CcSEcCtD
Boceprevir—CTSL—Immune System—CDKN1A—urinary bladder cancer	7.83e-05	0.000379	CbGpPWpGaD
Boceprevir—CTSV—Immune System—CDKN1A—urinary bladder cancer	7.83e-05	0.000379	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	7.81e-05	0.000378	CbGpPWpGaD
Boceprevir—CTSV—Immune System—PTEN—urinary bladder cancer	7.81e-05	0.000378	CbGpPWpGaD
Boceprevir—CTSL—Immune System—PTEN—urinary bladder cancer	7.81e-05	0.000378	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—FGFR3—urinary bladder cancer	7.72e-05	0.000374	CbGpPWpGaD
Boceprevir—Asthenia—Epirubicin—urinary bladder cancer	7.7e-05	0.000269	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	7.65e-05	0.00037	CbGpPWpGaD
Boceprevir—Pruritus—Epirubicin—urinary bladder cancer	7.6e-05	0.000265	CcSEcCtD
Boceprevir—CTSK—Immune System—ERBB2—urinary bladder cancer	7.59e-05	0.000367	CbGpPWpGaD
Boceprevir—Dizziness—Methotrexate—urinary bladder cancer	7.59e-05	0.000265	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	7.51e-05	0.000364	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ESR1—urinary bladder cancer	7.5e-05	0.000363	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CREBBP—urinary bladder cancer	7.46e-05	0.000361	CbGpPWpGaD
Boceprevir—CTSL—Immune System—EP300—urinary bladder cancer	7.45e-05	0.00036	CbGpPWpGaD
Boceprevir—CTSV—Immune System—EP300—urinary bladder cancer	7.45e-05	0.00036	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—EGFR—urinary bladder cancer	7.44e-05	0.00036	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CDH1—urinary bladder cancer	7.41e-05	0.000358	CbGpPWpGaD
Boceprevir—Diarrhoea—Epirubicin—urinary bladder cancer	7.35e-05	0.000257	CcSEcCtD
Boceprevir—Hypersensitivity—Doxorubicin—urinary bladder cancer	7.32e-05	0.000256	CcSEcCtD
Boceprevir—Vomiting—Methotrexate—urinary bladder cancer	7.29e-05	0.000255	CcSEcCtD
Boceprevir—CTSK—Innate Immune System—HRAS—urinary bladder cancer	7.25e-05	0.000351	CbGpPWpGaD
Boceprevir—CTSV—Immune System—SRC—urinary bladder cancer	7.24e-05	0.00035	CbGpPWpGaD
Boceprevir—CTSL—Immune System—SRC—urinary bladder cancer	7.24e-05	0.00035	CbGpPWpGaD
Boceprevir—Rash—Methotrexate—urinary bladder cancer	7.23e-05	0.000253	CcSEcCtD
Boceprevir—Dermatitis—Methotrexate—urinary bladder cancer	7.23e-05	0.000253	CcSEcCtD
Boceprevir—Headache—Methotrexate—urinary bladder cancer	7.19e-05	0.000251	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—EGFR—urinary bladder cancer	7.14e-05	0.000345	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	7.13e-05	0.000345	CbGpPWpGaD
Boceprevir—Asthenia—Doxorubicin—urinary bladder cancer	7.13e-05	0.000249	CcSEcCtD
Boceprevir—Dizziness—Epirubicin—urinary bladder cancer	7.1e-05	0.000248	CcSEcCtD
Boceprevir—Pruritus—Doxorubicin—urinary bladder cancer	7.03e-05	0.000246	CcSEcCtD
Boceprevir—CTSS—Innate Immune System—KRAS—urinary bladder cancer	7.02e-05	0.00034	CbGpPWpGaD
Boceprevir—CTSK—Adaptive Immune System—HRAS—urinary bladder cancer	6.96e-05	0.000337	CbGpPWpGaD
Boceprevir—CTSK—Immune System—IL2—urinary bladder cancer	6.88e-05	0.000333	CbGpPWpGaD
Boceprevir—Vomiting—Epirubicin—urinary bladder cancer	6.83e-05	0.000239	CcSEcCtD
Boceprevir—Nausea—Methotrexate—urinary bladder cancer	6.81e-05	0.000238	CcSEcCtD
Boceprevir—Diarrhoea—Doxorubicin—urinary bladder cancer	6.8e-05	0.000238	CcSEcCtD
Boceprevir—Rash—Epirubicin—urinary bladder cancer	6.77e-05	0.000237	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	6.76e-05	0.000327	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NAT1—urinary bladder cancer	6.76e-05	0.000327	CbGpPWpGaD
Boceprevir—Dermatitis—Epirubicin—urinary bladder cancer	6.76e-05	0.000236	CcSEcCtD
Boceprevir—CTSS—Adaptive Immune System—KRAS—urinary bladder cancer	6.75e-05	0.000326	CbGpPWpGaD
Boceprevir—Headache—Epirubicin—urinary bladder cancer	6.73e-05	0.000235	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	6.66e-05	0.000322	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CREBBP—urinary bladder cancer	6.57e-05	0.000318	CbGpPWpGaD
Boceprevir—Dizziness—Doxorubicin—urinary bladder cancer	6.57e-05	0.00023	CcSEcCtD
Boceprevir—CMA1—Signaling Pathways—IGF1—urinary bladder cancer	6.49e-05	0.000314	CbGpPWpGaD
Boceprevir—CTSK—Immune System—CDKN1A—urinary bladder cancer	6.48e-05	0.000314	CbGpPWpGaD
Boceprevir—CTSK—Immune System—PTEN—urinary bladder cancer	6.47e-05	0.000313	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	6.42e-05	0.000311	CbGpPWpGaD
Boceprevir—Nausea—Epirubicin—urinary bladder cancer	6.38e-05	0.000223	CcSEcCtD
Boceprevir—CTSL—Immune System—EGFR—urinary bladder cancer	6.35e-05	0.000307	CbGpPWpGaD
Boceprevir—CTSV—Immune System—EGFR—urinary bladder cancer	6.35e-05	0.000307	CbGpPWpGaD
Boceprevir—Vomiting—Doxorubicin—urinary bladder cancer	6.32e-05	0.000221	CcSEcCtD
Boceprevir—Rash—Doxorubicin—urinary bladder cancer	6.26e-05	0.000219	CcSEcCtD
Boceprevir—Dermatitis—Doxorubicin—urinary bladder cancer	6.26e-05	0.000219	CcSEcCtD
Boceprevir—CTSS—Immune System—ERBB2—urinary bladder cancer	6.25e-05	0.000302	CbGpPWpGaD
Boceprevir—Headache—Doxorubicin—urinary bladder cancer	6.22e-05	0.000217	CcSEcCtD
Boceprevir—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	6.19e-05	0.000299	CbGpPWpGaD
Boceprevir—CTSK—Immune System—EP300—urinary bladder cancer	6.17e-05	0.000299	CbGpPWpGaD
Boceprevir—CTSK—Immune System—SRC—urinary bladder cancer	6e-05	0.00029	CbGpPWpGaD
Boceprevir—CTSL—Immune System—KRAS—urinary bladder cancer	6e-05	0.00029	CbGpPWpGaD
Boceprevir—CTSV—Immune System—KRAS—urinary bladder cancer	6e-05	0.00029	CbGpPWpGaD
Boceprevir—CTSS—Innate Immune System—HRAS—urinary bladder cancer	5.97e-05	0.000289	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—RHOA—urinary bladder cancer	5.95e-05	0.000288	CbGpPWpGaD
Boceprevir—Nausea—Doxorubicin—urinary bladder cancer	5.9e-05	0.000206	CcSEcCtD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	5.88e-05	0.000285	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	5.86e-05	0.000283	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	5.83e-05	0.000282	CbGpPWpGaD
Boceprevir—CTSS—Adaptive Immune System—HRAS—urinary bladder cancer	5.73e-05	0.000277	CbGpPWpGaD
Boceprevir—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	5.73e-05	0.000277	CbGpPWpGaD
Boceprevir—CTSS—Immune System—IL2—urinary bladder cancer	5.66e-05	0.000274	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	5.57e-05	0.00027	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—ERBB2—urinary bladder cancer	5.5e-05	0.000266	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.41e-05	0.000262	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	5.38e-05	0.000261	CbGpPWpGaD
Boceprevir—CTSS—Immune System—CDKN1A—urinary bladder cancer	5.34e-05	0.000258	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.34e-05	0.000258	CbGpPWpGaD
Boceprevir—CTSS—Immune System—PTEN—urinary bladder cancer	5.33e-05	0.000258	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	5.26e-05	0.000255	CbGpPWpGaD
Boceprevir—CTSK—Immune System—EGFR—urinary bladder cancer	5.26e-05	0.000254	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CXCL8—urinary bladder cancer	5.22e-05	0.000253	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	5.13e-05	0.000248	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	5.11e-05	0.000247	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTO2—urinary bladder cancer	5.1e-05	0.000247	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NAT1—urinary bladder cancer	5.1e-05	0.000247	CbGpPWpGaD
Boceprevir—CTSL—Immune System—HRAS—urinary bladder cancer	5.1e-05	0.000247	CbGpPWpGaD
Boceprevir—CTSV—Immune System—HRAS—urinary bladder cancer	5.1e-05	0.000247	CbGpPWpGaD
Boceprevir—CTSS—Immune System—EP300—urinary bladder cancer	5.08e-05	0.000246	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	5.05e-05	0.000244	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—IL2—urinary bladder cancer	4.99e-05	0.000241	CbGpPWpGaD
Boceprevir—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	4.98e-05	0.000241	CbGpPWpGaD
Boceprevir—CTSK—Immune System—KRAS—urinary bladder cancer	4.97e-05	0.00024	CbGpPWpGaD
Boceprevir—CTSS—Immune System—SRC—urinary bladder cancer	4.94e-05	0.000239	CbGpPWpGaD
Boceprevir—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.91e-05	0.000237	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CCND1—urinary bladder cancer	4.86e-05	0.000235	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MMP9—urinary bladder cancer	4.72e-05	0.000228	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.7e-05	0.000228	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—PTEN—urinary bladder cancer	4.69e-05	0.000227	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	4.67e-05	0.000226	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—EP300—urinary bladder cancer	4.48e-05	0.000217	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—SRC—urinary bladder cancer	4.35e-05	0.000211	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.34e-05	0.00021	CbGpPWpGaD
Boceprevir—CTSS—Immune System—EGFR—urinary bladder cancer	4.33e-05	0.00021	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	4.28e-05	0.000207	CbGpPWpGaD
Boceprevir—CTSK—Immune System—HRAS—urinary bladder cancer	4.22e-05	0.000204	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	4.2e-05	0.000203	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	4.19e-05	0.000203	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—TYMP—urinary bladder cancer	4.1e-05	0.000198	CbGpPWpGaD
Boceprevir—CTSS—Immune System—KRAS—urinary bladder cancer	4.09e-05	0.000198	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	3.97e-05	0.000192	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—MYC—urinary bladder cancer	3.9e-05	0.000189	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PRSS3—urinary bladder cancer	3.87e-05	0.000187	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—EGFR—urinary bladder cancer	3.81e-05	0.000185	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	3.78e-05	0.000183	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NAT2—urinary bladder cancer	3.71e-05	0.000179	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	3.66e-05	0.000177	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	3.65e-05	0.000177	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—KRAS—urinary bladder cancer	3.6e-05	0.000174	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	3.48e-05	0.000168	CbGpPWpGaD
Boceprevir—CTSS—Immune System—HRAS—urinary bladder cancer	3.48e-05	0.000168	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	3.39e-05	0.000164	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.32e-05	0.00016	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—TP53—urinary bladder cancer	3.2e-05	0.000155	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—RRM2—urinary bladder cancer	3.2e-05	0.000155	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.14e-05	0.000152	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.14e-05	0.000152	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.09e-05	0.00015	CbGpPWpGaD
Boceprevir—CMA1—Signaling Pathways—HRAS—urinary bladder cancer	3.06e-05	0.000148	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.03e-05	0.000147	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	2.97e-05	0.000144	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	2.96e-05	0.000143	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ENO2—urinary bladder cancer	2.96e-05	0.000143	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.88e-05	0.000139	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	2.87e-05	0.000139	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	2.83e-05	0.000137	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	2.8e-05	0.000136	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NAT2—urinary bladder cancer	2.8e-05	0.000135	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.59e-05	0.000125	CbGpPWpGaD
Boceprevir—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	2.49e-05	0.000121	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.45e-05	0.000118	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—RRM2—urinary bladder cancer	2.41e-05	0.000117	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NQO1—urinary bladder cancer	2.39e-05	0.000116	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.38e-05	0.000115	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.24e-05	0.000108	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.24e-05	0.000108	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.17e-05	0.000105	CbGpPWpGaD
Boceprevir—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.03e-05	9.82e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	1.99e-05	9.64e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.91e-05	9.22e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—TYMS—urinary bladder cancer	1.85e-05	8.96e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	1.83e-05	8.86e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	1.83e-05	8.86e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.8e-05	8.72e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—GPX1—urinary bladder cancer	1.75e-05	8.48e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.72e-05	8.34e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	1.72e-05	8.33e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	1.62e-05	7.83e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.5e-05	7.27e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.49e-05	7.2e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.4e-05	6.76e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.38e-05	6.68e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.38e-05	6.68e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.38e-05	6.66e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.38e-05	6.66e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.34e-05	6.46e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.32e-05	6.4e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.31e-05	6.35e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.3e-05	6.28e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.26e-05	6.1e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.22e-05	5.91e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.11e-05	5.37e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.03e-05	4.99e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PPARG—urinary bladder cancer	9.9e-06	4.79e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—CREBBP—urinary bladder cancer	9.51e-06	4.6e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.26e-06	4.48e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—PTEN—urinary bladder cancer	9e-06	4.35e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.61e-06	4.17e-05	CbGpPWpGaD
Boceprevir—CYP3A5—Metabolism—EP300—urinary bladder cancer	8.58e-06	4.15e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.51e-06	4.12e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.51e-06	4.12e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.15e-06	3.94e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8e-06	3.87e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PTGS2—urinary bladder cancer	7.79e-06	3.77e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.52e-06	3.64e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—PTEN—urinary bladder cancer	6.79e-06	3.29e-05	CbGpPWpGaD
Boceprevir—ABCB1—Metabolism—EP300—urinary bladder cancer	6.48e-06	3.13e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.1e-06	2.95e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	5.86e-06	2.83e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.8e-06	2.32e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.18e-06	2.02e-05	CbGpPWpGaD
Boceprevir—CYP3A4—Metabolism—EP300—urinary bladder cancer	3.99e-06	1.93e-05	CbGpPWpGaD
